Anti-PD-1 antibodies such as pembrolizumab and nivolumab, as well as anti-PD-L1 antibodies like atezolizumab and durvalumab, have been approved for the treatment of advanced melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and other cancers making them the foremost therapeutic agents in the oncology field (54). The gene discussed is CD274; the disease is renal cell carcinoma.